 |
PDBsum entry 5cdy
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
5cdy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.1.1.100
- 3-oxoacyl-[acyl-carrier-protein] reductase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a (3R)-hydroxyacyl-[ACP] + NADP+ = a 3-oxoacyl-[ACP] + NADPH + H+
|
 |
 |
 |
 |
 |
(3R)-hydroxyacyl-[ACP]
|
+
|
NADP(+)
|
=
|
3-oxoacyl-[ACP]
|
+
|
NADPH
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Plos One
10:e0141543
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural Characterisation of FabG from Yersinia pestis, a Key Component of Bacterial Fatty Acid Synthesis.
|
|
J.D.Nanson,
J.K.Forwood.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Ketoacyl-acyl carrier protein reductases (FabG) are ubiquitously expressed
enzymes that catalyse the reduction of acyl carrier protein (ACP) linked
thioesters within the bacterial type II fatty acid synthesis (FASII) pathway.
The products of these enzymes, saturated and unsaturated fatty acids, are
essential components of the bacterial cell envelope. The FASII reductase
enoyl-ACP reductase (FabI) has been the focus of numerous drug discovery
efforts, some of which have led to clinical trials, yet few studies have focused
on FabG. Like FabI, FabG appears to be essential for survival in many bacteria,
similarly indicating the potential of this enzyme as a drug target. FabG enzymes
are members of the short-chain alcohol dehydrogenase/reductase (SDR) family, and
like other SDRs, exhibit highly conserved secondary and tertiary structures, and
contain a number of conserved sequence motifs. Here we describe the crystal
structures of FabG from Yersinia pestis (YpFabG), the causative agent of
bubonic, pneumonic, and septicaemic plague, and three human pandemics. Y. pestis
remains endemic in many parts of North America, South America, Southeast Asia,
and Africa, and a threat to human health. YpFabG shares a high degree of
structural similarity with bacterial homologues, and the ketoreductase domain of
the mammalian fatty acid synthase from both Homo sapiens and Sus scrofa.
Structural characterisation of YpFabG, and comparison with other bacterial FabGs
and the mammalian fatty acid synthase, provides a strong platform for virtual
screening of potential inhibitors, rational drug design, and the development of
new antimicrobial agents to combat Y. pestis infections.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |